Dr. John Cush RheumNow
4 years 4 months ago
May 2022 EMA meeting the CHMP recommended new indications for Cosentyx (juvenile PsA, Enthesitis-related arthritis), Olumiant (alopecia areata), Rinvoq (ulcerative colitis) and Xeljanz (ankylosing spondylitis). EMA approval pending https://t.co/KauDY6e8zS https://t.co/mmv4G9jHI7
Dr. John Cush RheumNow
4 years 4 months ago
NSAID use is not associated with increased COVID-19 severity, all-cause mortality, invasive ventilation, AKI, or ECMO in COVID-19 inpatients. 38-center retrospective cohort propensity matched of EHR data from the National COVID Cohort Collaborative. https://t.co/u6Id4WnLPT
Dr. John Cush RheumNow
4 years 4 months ago
Disease modification has been defined in multiple disease areas but no widely accepted definition exists for SLE. Learn about the benefits & why there’s a need to consider therapies that modify the immunologic mechanisms of SLE. Sponsored by GSK USMA https://t.co/012Wk0d9Uu https://t.co/yteiuKDLLL
The acute consequences of a SARS-CoV-2 infection may be bothersome or devastating, but the long-term consequences may lead to so-called "long COVID" syndrome. Long COVID appears to affect up to 20% of those who survive COVID-19 infection.
Dr. John Cush RheumNow
4 years 4 months ago
Study of 282 inflammatory arthritis (IA) pts Rx with TNFi, 11 (3/9%) had neutralizing anti-drug Abs (nADAb). nADAb+ was more likely in smokders; such had significantly worse Dz activity, physical function, & inflammatory markers https://t.co/TnEKGpTQ85 https://t.co/I0hv5X35P1
Dr. John Cush RheumNow
4 years 4 months ago
""It's easy to make a buck. It's a lot tougher to make a difference." - Tom Brokaw
Dr. John Cush RheumNow
4 years 4 months ago
NEJM Case: 73 yoM w/ 1 mo hx of fatigue & diffuse bone pain, pancytopenia (no abd pain, neuro Sx of HSM). WBC 1.7, Hgb 5.9, P111k, MRI shows AVN femura & Humerus. Bone marrow bx revealed macrophages w/ “wrinkled tissue paper” https://t.co/raObXpTHBr https://t.co/U6nQnPKtqI
Dr. John Cush RheumNow
4 years 4 months ago
Medscapes list of Best & Worst States to Practice
Best 5: 1) Idaho 2) Georgia 3) S. Dakota 4) Texas 5) Indiana
Worst 5: 1)Maine 2)Maryland 3)W.Virginia 4)Rhode Island 5)Wash DC
https://t.co/4faJiy9l3D https://t.co/k9WKqo8pah
Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists.
SGLT2 inhibitors are all the buzz in the renal world with reports of a renal protective and mortality lowering effects. Maybe these agents should be considered and studied in lupus nephritis and ANCA- associated vasculitis.
Both old and newer pharmacological treatments for fibromyalgia are often promoted; but a recent systematic review and network meta-analysis showed that duloxetine had higher efficacy in pain and depression, while amitriptyline had higher efficacy in treating sleep, fatigue, and quality of life outcomes.
